Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Letrozole + Palbociclib + PF-06952229|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Letrozole||Femara||Letrozol||Aromatase Inhibitor 3||Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov).|
|PF-06952229||PF06952229|PF 06952229||TGFBR1 inhibitor 13||PF-06952229 is an inhibitor of the transforming growth factor-beta receptor 1 (TGFBR1), which results in stimulation of the immune system (NCI Drug Dictionary).|
|Palbociclib||Ibrance||PD0332991||CDK4/6 Inhibitor 9||Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03685591||Phase I||PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229||PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors||Recruiting|